LM
Lauren Merendino
Chief Commercial Officer

Lauren Merendino insider trades: Day One Biopharmaceuticals (DAWN) stock sales

Chief Commercial Officer, Day One Biopharmaceuticals Last trade Feb 17, 2026 15 Form 4 filings
$101K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2022
3
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Lauren reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Feb 17, 2026DAWN↓ Sell$67K
Nov 17, 2025DAWN↓ Sell$33K
Aug 18, 2025DAWN↓ Sell$25K
May 16, 2025DAWN↓ Sell$25K
Jan 18, 2023MYOV↓ Sell$54K
Oct 18, 2022MYOV↓ Sell$43K
Jul 18, 2022MYOV↓ Sell$22K
Apr 19, 2022MYOV↓ Sell$74K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other DAWN insiders

Open-market trades in the last 12 months

About Lauren Merendino's insider trades

Lauren Merendino is Chief Commercial Officer at Day One Biopharmaceuticals (DAWN). Since Apr 19, 2022, Lauren has reported no open-market purchases and 8 sales worth $343K on SEC Form 4. In the last 12 months: 2 sales ($101K).

Their filings also include grants and awards (5 filings), option exercises (4 filings), shares returned to the company (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DAWN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.